✦ LIBER ✦

934 POSTER Phase II study of irinotecan and oral etoposide in patients with platinum/taxane-resistant ovarian carcinoma

Book ID: 118623510
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 144 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)81229-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Oral Etoposide and Int

Phase II Study of Oral Etoposide and Intravenous Irinotecan for Patients with Platinum-resistant and Taxane-pretreated Ovarian Cancer: Japan Clinical Oncology Group Study 0503

✍ Matsumoto, K.; Katsumata, N.; Saito, I.; Shibata, T.; Konishi, I.; Fukuda, H.; K 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 74 KB

Sequential topotecan and oral etoposide

Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane : Results from a multicenter Phase I/II study

✍ Bo Gronlund; Svend A. Engelholm; György Horvath; Johanna Mäenpää; Mona Ridderhei 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND The objectives of this study were to determine the maximum tolerable dose (MTD), toxicity, efficacy, and feasibility of a sequential regimen of fixed‐dose topotecan (1.00 mg/m^2^ on Days 1–5) and increasing doses of oral etoposide (50 mg, 75 mg, and 100 mg on Days 6–12 or

Pilot study evaluating the efficacy and

Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer

✍ Shin Nishio; Toru Sugiyama; Tadahiro Shouji; Akira Yoshizaki; Ryo Kitagawa; Kimi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase II study of bevacizumab with lipos

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

✍ Verschraegen, C. F.; Czok, S.; Muller, C. Y.; Boyd, L.; Lee, S. J.; Rutledge, T. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 144 KB

Second-Line Treatment with Intravenous G

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

✍ Bruzzone, M.; Centurioni, M.G.; Giglione, P.; Gualco, M.; Merlo, D.F.; Miglietta 📂 Article 📅 2011 🏛 S. Karger AG 🌐 English ⚖ 469 KB

926 POSTER Phase II austrian AGO study o

926 POSTER Phase II austrian AGO study of pegylated liposomal doxorubicin and gemcitabine in platinum-refractory and resistant ovarian cancer following previous platinum-taxane therapy

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 266 KB